A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer

Nature Communications

Volumn 7, Issue , 2016, Pages

  Wu, Sherry Y ^a   Rupaimoole, Rajesha ^a   Shen, Fangrong ^a,b   Pradeep, Sunila ^a   Pecot, Chad V ^a,c   Ivan, Cristina ^a   Nagaraja, Archana S ^a   Gharpure, Kshipra M ^a   Pham, Elizabeth ^a,d   Hatakeyama, Hiroto ^a   McGuire, Michael H ^a   Haemmerle, Monika ^a   Vidal Anaya, Viviana ^a   Olsen, Courtney ^a   Rodriguez Aguayo, Cristian ^a   Filant, Justyna ^a   Ehsanipour, Ehsan A ^a   Herbrich, Shelley M ^a   Maiti, Sourindra N ^a   Huang, Li ^a   Kim, Ji Hoon ^a   Zhang, Xinna ^a   Han, Hee Dong ^a,e   Armaiz Pena, Guillermo N ^a   Seviour, Elena G ^a   Tucker, Sue ^a   Zhang, Min ^f   Yang, Da ^f   Cooper, Laurence J N ^a   Ali Fehmi, Rouba ^g   Bar Eli, Menashe ^a   Lee, Ju Seog ^a   Ram, Prahlad T ^a   Baggerly, Keith A ^a   Lopez Berestein, Gabriel ^a,c   Hung, Mien Chie ^a,h   Sood, Anil K ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d Canada   (Canada)

^e Konkuk University School of Medicine   (South Korea)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; EARLY GROWTH RESPONSE FACTOR 1; INTERLEUKIN 6; LIPOSOME; MICRORNA 192; PROTEIN; PROTEIN HOXB9; UNCLASSIFIED DRUG; 1,2-OLEOYLPHOSPHATIDYLCHOLINE; EGR1 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; HOXB9 PROTEIN, HUMAN; MICRORNA; MIRN192 MICRORNA, HUMAN; PHOSPHATIDYLCHOLINE;

ANTIBODY; CANCER; CELLS AND CELL COMPONENTS; DISEASE TREATMENT; EXPERIMENTAL STUDY; INHIBITION; RNA; TUMOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BINDING SITE; CANCER INHIBITION; CANCER SURVIVAL; CAPILLARY DENSITY; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY TUMOR; MOUSE; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PATIENT CODING; PHENOTYPE; SIGNAL TRANSDUCTION; STAINING; TUMOR REGRESSION; ANIMAL; DOWN REGULATION; GENE REGULATORY NETWORK; GENE THERAPY; GENETICS; KIDNEY NEOPLASMS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); OVARIAN NEOPLASMS; PHYSIOLOGY; TUMOR CELL LINE; TUMOR VOLUME; VASCULARIZATION;

ANIMALS; CELL LINE, TUMOR; DOWN-REGULATION; EARLY GROWTH RESPONSE PROTEIN 1; FEMALE; GENE REGULATORY NETWORKS; GENETIC THERAPY; HOMEODOMAIN PROTEINS; HUMANS; KIDNEY NEOPLASMS; MICE; MICRORNAS; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PHOSPHATIDYLCHOLINES; TUMOR BURDEN;

EID: 84962728482     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11169     Document Type: Article

References (57)

1. Bottsford-Miller, J., Coleman, R. & Sood, A. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J. Clin. Oncol. 30, 4026-4034 (2012).
2. Burger, R. et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 365, 2473-2483 (2011).
3. Perren, T. et al. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 365, 2484-2496 (2011).
4. Fernando, N. et al. Tumor escape from endogenous, extracellular matrixassociated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin. Cancer Res. 14, 1529-1539 (2008).
5. Kopetz, S. et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J. Clin. Oncol. 28, 453-459 (2010).
6. Batchelor, T. et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83-95 (2007).
7. Casanovas, O., Hicklin, D., Bergers, G. & Hanahan, D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299-309 (2005).
8. Ebos, J., Lee, C., Christensen, J., Mutsaers, A. & Kerbel, R. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc. Natl Acad. Sci. USA 104, 17069-17074 (2007).
9. Ling, H., Fabbri, M. & Calin, G. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat. Rev. Drug Discov. 12, 847-865 (2013).
10. Starmans, M. et al. The prognostic value of temporal in vitro and in vivo derived hypoxia gene-expression signatures in breast cancer. Radiother. Oncol. 102, 436-443 (2012).
11. Kim, T. et al. p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J. Exp. Med. 208, 875-883 (2011).
12. Komurov, K., Dursun, S., Erdin, S. & Ram, P. NetWalker: a contextual network analysis tool for functional genomics. BMC Genomics 13, 282 (2012).
13. Shankavaram, U. et al. CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics 10, 277 (2009).
14. Yang, D. et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell 23, 186-199 (2013).
15. Rupaimoole, R. et al. Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat. Commun. 29, 5202 (2014).
16. Pecot, C. et al. Tumour angiogenesis regulation by the miR-200 family. Nat. Commun. 4, 2427 (2013).
17. Wu, S., Lopez-Berestein, G., Calin, G. & Sood, A. RNAi therapies: drugging the undruggable. Sci. Transl. Med. 6, 240ps247 (2014).
18. Merritt, W. et al. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol. Ther. 8, 1596-1603 (2009).
19. Hong, J., Li, X., Li, M. & Zheng, F. VEGF suppresses epithelial-mesenchymal transition by inhibiting the expression of Smad3 and miR-192, a Smad3-dependent microRNA. Int. J. Mol. Med. 31, 1436-1442 (2013).
20. Posadas, E., Limvorasak, S., Sharma, S. & Figlin, R. Targeting angiogenesis in renal cell carcinoma. Expert Opin. Pharmacother. 14, 2221-2236 (2013).
21. Braun, C. et al. p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res. 68, 10094-10104 (2008).
22. Pichiorri, F. et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 18, 367-381 (2010).
23. Chiang, Y. et al. microRNA-192, -194 and -215 are frequently downregulated in colorectal cancer. Exp. Ther. Med. 3, 560-566 (2012).
24. Khella, H. et al. miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma. Carcinogenesis 34, 2231-2239 (2013).
25. Senanayake, U. et al. miR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms. Carcinogenesis 33, 1014-1021 (2012).
26. Feng, S. et al. MicroRNA-192 targeting retinoblastoma 1 inhibits cell proliferation and induces cell apoptosis in lung cancer cells. Nucleic Acids Res. 39, 6669-6678 (2011).
27. Patterson, D. et al. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma. Angiogenesis 14, 255-266 (2011).
28. Kato, M. et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc. Natl Acad. Sci. USA 104, 3432-3437 (2007).
29. Wang, B. et al. E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes 59, 1794-1802 (2010).
30. Mudduluru, G. et al. A systematic approach to defining the microRNA landscape in metastasis. Cancer Res. 75, 3010-3019 (2015).
31. Nam, R. et al. Identification and validation of a five microRNA signature predictive of prostate cancer recurrence and metastasis: a cohort study. J. Cancer 6, 1160-1171 (2015).
32. Hur, K. et al. Identification of a metastasis-specific MicroRNA signature in human colorectal cancer. J. Natl Cancer Inst. 107, dju492 (2015).
33. Ungewiss, C. et al. The microRNA-200/Zeb1 axis regulates ECM-dependent b1-integrin/FAK signaling, cancer cell invasion and metastasis through CRKL. Sci. Rep. 6, 18652 (2016).
34. Geng, L. et al. MicroRNA-192 suppresses liver metastasis of colon cancer. Oncogene 33, 5332-5340 (2014).
35. Valencia, K. et al. miRNA cargo within exosome-like vesicle transfer influences metastatic bone colonization. Mol. Oncol. 8, 689-703 (2014).
36. Abdel-Malak, N., Mofarrahi, M., Mayaki, D., Khachigian, L. & Hussain, S. Early growth response-1 regulates angiopoietin-1-induced endothelial cell proliferation, migration, and differentiation. Arterioscler. Thromb. Vasc. Biol. 29, 209-216 (2009).
37. Singha, B. et al. Proteasome inhibition increases recruitment of IkB kinase b (IKKb), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells. J. Biol. Chem. 289, 2687-2700 (2014).
38. Kundumani-Sridharan, V. et al. 15(S)-hydroxyeicosatetraenoic acid-induced angiogenesis requires Src-mediated Egr-1-dependent rapid induction of FGF-2 expression. Blood 115, 2105-2116 (2010).
39. Shimoyamada, H. et al. Early growth response-1 induces and enhances vascular endothelial growth factor-A expression in lung cancer cells. Am. J. Pathol. 177, 70-83 (2010).
40. Lee, K. & Kim, J. Hepatocyte growth factor induced up-regulations of VEGF through Egr-1 in hepatocellular carcinoma cells. Clin. Exp. Metastasis 26, 685-692 (2009).
41. Shrestha, B. et al. Homeodomain-containing protein HOXB9 regulates expression of growth and angiogenic factors, facilitates tumor growth in vitro and is overexpressed in breast cancer tissue. FEBS J. 279, 3715-3726 (2012).
42. Myung, D. et al. Expression of early growth response-1 in colorectal cancer and its relation to tumor cell proliferation and apoptosis. Oncol. Rep. 31, 788-794 (2014).
43. Ghanem, M. et al. Expression and prognostic value of Wilms tumor 1 and early growth response 1 proteins in nephroblastoma. Clin. Cancer Res. 6, 4265-4271 (2000).
44. Eid, M., Kumar, M., Iczkowski, K., Bostwick, D. & Tindall, D. Expression of early growth response genes in human prostate cancer. Cancer Res. 58, 2461-2468 (1998).
45. Zhan, J. et al. High expression of transcriptional factor HoxB9 predicts poor prognosis in patients with lung adenocarcinoma. Histopathology 66, 955-965 (2014).
46. Seki, H. et al. HOXB9 expression promoting tumor cell proliferation and angiogenesis is associated with clinical outcomes in breast cancer patients. Ann. Surg. Oncol. 19, 1831-1840 (2012).
47. Apte, S., Bucana, C., Killion, J., Gershenson, D. & Fidler, I. Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecol. Oncol. 93, 78-86 (2004).
48. Vivas-Mejia, P. et al. Silencing survivin splice variant 2B leads to antitumor activity in taxane-resistant ovarian cancer. Clin. Cancer Res. 17, 3716-3726 (2011).
49. Landen, C. J. et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65, 6910-6918 (2005).
50. Wu, S. et al. 2-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat. Commun. 5, 3459 (2014).
51. Pradeep, S. et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell 26, 77-91 (2014).
52. Hatakeyama, H., Wu, S., Mangala, L., Lopez-Berestein, G. & Sood, A. Assessment of in vivo siRNA delivery in cancer mouse models. Methods Mol. Biol. 1402, 189-197 (2016).
53. Zuo, Z. et al. Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. Mod. Pathol. 28, 373-382 (2015).
54. Komurov, K., White, M. & Ram, P. Use of data-biased random walks on graphs for the retrieval of context-specific networks from genomic data. PLoS Comput. Biol. 6, e1000889 (2010).
55. Merritt, W. et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N. Engl. J. Med. 359, 2641-2650 (2008).
56. Armaiz-Pena, G. et al. Src activation by b-adrenoreceptors is a key switch for tumour metastasis. Nat. Commun. 4, 1403 (2013).
57. Dweep, H., Sticht, C., Pandey, P. & Gretz, N. miRWalk-database: prediction of possible miRNA binding sites by walking the genes of 3 genomes. J. Biomed. Inform. 44, 839-847 (2011).